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Abstract: Medical textiles are a highly specialised stream of technical textile!! industry with a growing 
range of applications. A significant advancement has been achieved in surgical products or biomedical 
textiles (implantable/non-implantable) with the advent of 3D textile manufacturing techniques. 
Cardiovascular soft tissue implants (vascular grafts) have been a field of interest over decades for use of 
innovative 3D tubular structures in treatment of cardiovascular diseases. In the field of soft tissue 
implants, knitted and woven tubular structures are being used for large diameter blood vessel 
replacements. Advent of electrospinning and tissue engineering techniques has been able to provide 
promising answers to small diameter vascular grafts. The aim of this review is to outline the approaches 
in vascular graft development utilising diffetent 3D tubular structure forming techniques. The emphasis is 
on vascular graft development techniques that can help improve treatment efficacy in future. 
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1. Introduction 
Cardiovascular diseases are the leading cause of death in the developed world due to continuing increase 
in aging population. This has led to an increased demand on blood vessel replacement and hence the demand 
of artificial vascular grafts. Atherosclerosis is a common and widespread cardiovascular disease caused by 
deposition of plaque on the inner surface of blood vessel and hence causing vessel occlusion. A surgical 
bypass of blood vessels on the heart or on a lower extremity is performed for atherosclerosis treatment. 
A variety of biologic grafts and synthetic prostheses are commercially available, each with distinct 
qualities and potential applications [1]. Autologous grafts are preferred for small-vessel reconstruction, and 
synthetic prostheses are best suited for large-vessel replacement. Long-term patency rates of synthetic grafts 
are satisfactory in large-calibre arteries (> 8 mm ID), where disposition to blood coagulation is overcome by 
high blood flow rate. However, in small-calibre vessels (< 6 mm ID), such as coronary arteries (heart), the 
performance of synthetic prostheses is unacceptable. Compliance mismatch between the natural vessel and 
the synthetic vascular graft at the anastomoses is considered to be the cause of intima hyperplasia and 
reduced patency rates of these grafts. Such drawbacks of synthetic grafts incline the surgeons to prefer the 
use of autologous grafts (from within the patient body) for small artery bypass. Nevertheless, factors such as 
accelerated atherosclerotic changes, donor site morbidity, need for additional harvest and previous harvest 
limit the use of autografts even. Since there is currently no clinically acceptable synthetic small diameter 
vascular graft, perhaps one of the innovative technologies in textile manufacturing may revolutionize the 
field of vascular surgery. The ultimate aim of any improvement step in design of such grafts is to achieve a 
grfats which [2]: 
• is biocompatible (non-thrombogenic, non-immunogenic, non-inflammatory) 
• induces an appropriate healing response 
• remodels well including ease of endothelium regrowth 
• possesses adequate mechanical properties (compliance, strength, creep resistance, permeabilify, 
stiffness, nonlinearity) 
• easy to handle and deploy (suturability, flexibility) 
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• easily available in different specifications readily 
• can be easily manufactured in short time span 
2. Evolution of vascular grafts 
Vascular surgery tracks its way back to 1902 with the initial work of Alexis Carrel on optimising 
vascular anastomosis transplantation and organ replacement technique [3]. Further in 1907, Lexer used the 
first autologous vein (saphenous vein) for replacing an axillary artery defect [4]. The use of an artificial 
synthetic graft was reported first in 1952 by Voorhees by presenting Vinyon 'N' cloth tubes as a replacement 
for arterial defects in dogs [5]. The feasibility of such fabric tubes was confirmed by the same authors in 
1954 on human abdominal aorta [6]. This led to an instant breakthrough in vascular surgery for potential use 
of synthetic vascular prostheses. The late 1950s and 1960s marked the onset of widespread use of Dacron 
(Polyethylene terephthalate, PET; 1957) and Teflon (expanded Polytetraflouroethylene, ePTFE; 1970) based 
vascular grafts in vascular surgery [7]. 
3. Vascular replacement strategies 
3.1 Current vascular grafts (Large and medium diameter) 
After the successful experiments of Voorhees in 1952 on synthetic materials, two major polymers, PET 
(Polyethylene terephthalate) and ePTFE (expanded Polytetraflouroethylene), started being used extensively 
for manufacturing of synthetic vascular grafts. Dacron grafts are generally constructed from multifilament 
textured yarns using either weaving or knitting [1]. Woven grafts, due to their tight structure, are nonporous 
and low in stretchability. Woven Dacron grafts possess poor handling characteristics and suffer from poor 
compliance match. Knitted grafts have a more elastic and porous structure than woven grafts. For enhancing 
the pre-clotting and tissue growth on the knitted grafts, generally a velour structure is formed creating a 
velvet effect on either the outer or inner surface of the graft. Highly porous knitted grafts are made 
impervious by impregnation or coating with albumin/collagen to minimize blood loss in initial stages of 
implantation. Dacron grafts are generally used as a large-diameter graft (7-9 mm) and studies have shown 
lowered patency rates with smaller vessel diameters(< 6 mm) [8]. 
ePTFE is an ine1t fluorocarbon polymer and is considered to be more biostable and better performing 
than Dacron grafts for medium diameter grafts due to its electronegative lurninal surface that is 
antithrombotic and the presence of solid nodes with interconnecting small fibrils. The pore size is defined as 
internodal distance (IND) on the surface of graft. Considering the performance of ePTFE for small diameter 
vascular replacement, some researchers investigated new techniques to develop ePTFE grafts to perform 
better in small diameter regions. Hayashi et al. [9] succeeded in the development of ePTFE vascular graft 
that featured high porosity and large pore size as well as ~igh water entry pressure and high mechanical 
strength. Implantation of this new ePTFE vascular graft (ID· 4 mm) to canine models resulted in substantial 
improvement of graft patency (about 80% of grafts remained patent after twelve weeks). However, 
contradicting clinical studies of ePTFE grafts have shown primary and secondary patency in range of 12-25% 
after 5 years of implantation in infra-popliteal prosthetic graft bypass [10, 11]. Also a one year follow up 
study comparing autografts and ePTFE grafts showed that 86% of the vein grafts were patent while only 59% 
of ePTFE grafts were patent [12]. Chard et al. [13] found that ePTFE as coronary bypass grafts were 86% 
patent at 1 week, 64% at 12 months, 32% at 24 months, 21% at 36 months, and only 14% at 45 months. 
Therefore, ePTFE grafts are considered as an option if autologous vein grafts are not available or 
contraindicated [14]. 
The primary area of failure in prosthetic grafting with Dacron and PTFE is the patency of small-calibre 
grafts (< 5 mm ID), which remains poor. The inherent thrombogenicity of these prosthetic grafts in 
conjunction with neointimal hyperplasia, which is limited to the anastomotic area, is the prime factors for the 
failure. The seeding of prosthetic grafts with endothelial cells and subsequent proliferation of these cells into 
a confluent monolayer along the graft can be seen as an attractive solution to this problem. 
3.2 Improvement steps in vascular grafts 
3.2.1 Surface modified grafts 
The poor biocompatibility of synthetic materials and the persistent drawbacks of clinically unacceptable 
graft diameters ( < 6 mm) created the need to improve clinical performance using surface modification of 
these grafts. A common method of surface fuctionalisation of Dacron grafts is with a radiofrequency glow 
discharge process (RFGD). Results have shown that Dacron vascular grafts treated with tetrafluoroethylene 
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during an RFGD process, resist thrombus deposition, embolization and thrombotic occlusion compared to 
normal PET or PTFE surfaces [15]. Desired functiona1 groups can be inlroduced on to the surface of grafts 
that can later be used to immobilize specific proteins. Hydrolyzation technique was employed for Polyester 
(PET) with Sodium hydroxide (NaOH), for creating carboxyl groups at the sutface. The modified surface 
provided sites for covalent attachment of plasma albumin, thus creating a surface with improved 
biocompatibility [16]. PTFE was modified using ammonia plasma or alkylamine plasma to covalently bind 
collagen, fibronectin, which improved adhesion of endothelial cells to the surface [ 17, I SJ. Gamma radiation 
has also been utilised for surface modification trials. In the simultaneous grafting procedure, substrate and 
monomer are irradiated simultaneously. It was observed that growth of endothelial cells (ECs) on 
polyethylene, polyamide and ePTFE significantly improved after grafting a mixture of hydroxyethyl 
methacrylate and N-vinylpyrrolidone [19]. Ohgoe et al. [20] coated a -C:H film onto inner-wall of a 
synthetic vascular graft, which was made of expanded form polytetrafluoroethylene (ePTFE) using radio 
frequency plasma CVD technique with cylindrical electrode. The a-C:H film coating provided cell viability 
and presented improvement of cytocompatibility of the ePTFE vascular graft. 
3.2.2 Coated and impregnated grafts 
Chemical modification of graft surface using a coating can help improve binding of collagen, gelatin and 
albumin to the surface of vascular grafts and works as a sealant to block the pores on the surface [21]. 
Commonly used sealants like collagen and gelatin have been investigated on vascular grafts and showed 
good long-term patency, without formation of thrombosis or hyperplasia and performed better than ePTFE 
grafts- [22]. Albumin coated vascular grafts have also shown improved biocompatibility in clinical trials on 
animal models [23, 24]. Heparin bonded Dacron and ePTFE grafts showcased better patency and 
thromboresistance than an untreated ePTFE graft in different experiments [25-27]. A gelatin-sealed warp 
knit polyester arterial prosthesis was implanted as thoraco-abdominal bypass, which showed greater 
dimensional stability than the Dacron grafts when implanted in dogs for one year [28]. Addition of specific 
growth factors has also been applied to vascular grafts as sealants, like acidic and basic fibroblast growth 
factor (aFGF/bFGF). These growth factors are added to the sealant in combination with heparin [29, 30]. 
Impregnation of grafts with specific compounds is also performed to reduce the risk of vascular graft 
infection by adding antibiotics to graft sealants. A silver-coated collagen-impregnated Dacron prosthesis has 
also been shown to assist in the treatment of vascular graft infection [31]. 
3.2.3 Endothelial cell seeded grafts 
Thrombogenicity is inherent to the surface characteristics of implanted synthetic graft materials that lack 
a functional intima, known as endothelial cell lining. One proposed solution to this problem of small-
diameter graft thrombogenicity has been to grow a monolayer of endothelial cells on the luminal surface of a 
synthetic graft in order to improve their long term patency [32-34]. Endothelial cell seeding technique was 
initiated by Herring [33] in 1978 by isolating canine venous ECs to preclot porous Dacron prostheses and 
then implanting in the infrarenal aorta of dogs. The seeded grafts demonstrated 76% patency to thrombus 
against 22% for non-seeded grafts. In a later study, seeding ofECs on ePTFE grafts in a canine model was 
investigated by Graham et al. [35]. Since inception of the concept EC seeding, numerous methodologies for 
EC seeding have been developed but further development is still underway to make this procedure available 
to surgeons in the operating room [36, 37]. 
A major concern with seeding ePTFE grafts is the potential delamination of the layer upon implantation 
due to surgical, mechanical manipulation and subsequent exposure to blood shear stress [38]. Endothelial 
cell seeding technique suffers from the shortcomings of limited number of potentially available cells in 
autologous veins, low efficiency of harvest and degree of adherence [39]. It was studied and concluded by 
Williams et al. [ 40] in 1985 that EC adherence increases when the grafts are coated with extracellular matrix, 
plasma or fibronectin. For improving the clinical success, additional cell sources and cell retention 
technologies have been trialled. Therefore, in order to regulate cell attachment, biomaterials are coated with 
ECM (Extra cellular matrix) proteins such as collagen, laminin and fibronectin [41] or by covalent bonding 
of short adhesive peptides. However it was later found out that fibronectin coating not only increased 
adhesion of cells but helds platelets on to the surface, thus reducing the patency of the coated grafts [ 42-44]. 
Another major limitation of cell seeding procedure is that it requires substantial cell culture period to allow 
for cell adhesion and neointima formation [32]. 
3.2.4 Compound or bicomponent grafts 
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An important criterion in an absorbable scaffold development, as with other applications, is establishing 
sufficient mechanical strength prior to absorption of absorbable component. If this is not feasible, the 
absorbable scaffold may be reinforced by an inert component or developed into a composite material 
whereby the tissue ingrowth occurs and hence results in a bicomponent graft. 
Wesolowski et al. [ 45] pioneered the work in development of absorbable polymers in vascular grafts for 
the first time in 1960. The authors employed bicomponent fabrics consisting of absorbable materials in three 
different configurations: collagen coated nylon or Dacron mesh, a taffeta tube with Dacron warp and 
composite (Dacron and collagen) weft yarn and a taffeta tube with Dacron warp yams and collagen core 
wrapped with Dacron as filling yams. The developed grafts were implanted in animal models and compound 
grafts were found to perform better than coated grafts. Later, Bowald et al. [ 46] compared double layer 
Vicryl grafts with Vicryl grafts/ePTFE or Dacron mesh grafts in animal models. The bicomponent grafts 
performed better than single polymer grafts with increased collagen formation. Uretzky et al. [47] developed 
compound knitted and woven Dacron vascular prosthesis coated with a polymeric biodegradable sealant 
(Polyethylene oxidepolylactic acid) and implanted in right ventricular conduits in dogs. The results indicated 
superior healing properties of the selectively biodegradable grafts, increased long-term patency and 
decreased complication of right ventricular conduits. 
3.3 Future technologies in small calibre grafts 
3.3.1 Tissue engineered vascular grafts 
In order to present a solution to problems and shortcomings of synthetic (absorbable and non-absorbable) 
materials involved in fulfilling the numerous ideal graft characteristics, biomaterials research shifted towards 
innovative technologies of nanotechnology and tissue engineering for vascular graft development. Tissue-
engineering (TE) is an interdisciplinary field that applies the principles of engineering and life sciences to the 
development of biological substitutes in order to restore, maintain, or improve tissue functions [48]. Tissue 
engineered grafts have the ability to remodel, grow, self-repair and respond to the immediate environment, 
display desirable viscoelastic properties and are free from any synthetic foreign material that would initiate 
chronic inflammatory responses or be susceptible to infection [ 49]. 
A scaffold is a major component of a tissue-engineered vascular graft responsible for providing initial 
graft shape and strength, organisation and differentiation of seeded cells [50]. Scaffolds can be synthetic 
(degradable/non-degradable), biological materials (collagen) and natural (De-cellularised hollow organs, cell 
sheets). It has been found that non-degradable scaffolds generally do not present a clinically successful 
bypass graft [51]. Weinberg and Bell were first to develop a vascular graft using a Dacron scaffold and 
culturing bovine fibroblasts and SMC and then seeding with ECs [52]. A scaffold should be gradually 
removed and replaced by the newly-forming tissue and the resulting graft is termed as a hybrid graft. 
Biodegradable scaffolds provide temporary support for vascu,lar tissue regeneration and then degrade to be 
replaced by newly-forming tissue [53]. In a study involving a biodegradable scaffold, bovine arterial SMC 
and EC were seeded onto the polymer matrix (Polyglycolic acid, PGA) scaffold, and the resulting vascular 
grafts showcased good strength and collagen content results near to natural artery when implanted in animal 
models [54]. Torikai et al. [55] developed a graft (ID 10 mm) comprised of an interior of knitted 
polyglycolic acid compounded with collagen acting as a scaffold for tissue growth and an exterior of woven 
poly-L-lactic acid for reinforcement. 
Tissue-engineering of vascular bypass grafts is a fast advancing field stimulated by the large number of 
bypass procedures carried out without available autologous vein and the lack of synthetic prostheses with 
good long-term results. A full tissue-engineered artery has been an attractive option. However, exact pore 
specifications present great challenges in scaffold engineering [56]. New innovations in the field of 
nanotechnology in material science have significantly improved the performance of scaffolds. Nanofibre 
manipulations of established polymers can achieve the favourable properties for biological implants. At 
present, in-vi\?o approaches to regenerating tissue in a patient seems more promising than the ex-vivo 
construction of organs. But a significant limiting factor of fully TE grafts is the long time period (approx ~8 
weeks) required before an individualised graft can be made available and thus precludes their use m 
emergency cardiology. The prolonged duration of culture needed to produce the graft increases the risk of 
infection and cell transformation and raises the cost in terms of manpower, equipment and materials as well. 
3.3.2 Electrospun vascular grafts (3D tubular constructs) 
Almost all of the human tissues and organs are constructed in nanofibrous forms or structures. Each of 
them is characterized by well organized hierarchical fibrous structures in nanometer scale. This has led the 
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researchers to look for different polymeric materials. Human cells can attach and organize well around fibers 
with diameters smaller than those of the cells. Electrospinning method can be utilised to construct three-
dimensional (3D) synthetic polymeric grafts with mechanical properties comparable to native vascular tissue 
[57]. 
Xu et al. [58] and Mo et al. r59] suggest that the synthetic polymer scaffold poly(L-lactide-co-11 -
caprolactone) (P(LLA-CL)) composed of aligned and random nanofibres, mimics the native extracellular 
matrix. Wu et al. [60] developed electrospun PCL nanofibrous tubular scaffolds (ID 4.5 mm) with different 
nanofibre orientations and concluded that oriented nanofibers had directional mechanical property alongwith 
a high degree of endothelial cell attachment on the fibres. Vascular constructs using natural collagen material 
and its blend have been developed using nanofibres (100-150 nm) in separate studies for tissue-engineering 
scaffolds applications [61, 62]. The same authors developed elastin nano.fibres from peptide polymers for 
similar applications [63]. Stitzel et al. [64] fabricated a fibrous graft (4.5 mm ID) from electrospun fibres of 
polymer mixture of collagen type I, elastin and PLGA. The grafts demonstrated a compliance of 12-14% 
within the physiologic pressure range. Yang et al. [65] prepared electrospun composite mats of PLGA and 
collagen where blending of collagen with PLGA was found to enhance the cell attachment and proliferation 
and extracellular matrix secretion. 
Silk fibroin (SF) has also been a material of interest for many researchers to be used as electrospun 
tubular grafts [66]. Soffer et al. [67] fabricated nonwoven nanofibrous tubular structures from Bombyx mori 
silk fibroin seeded with human endothelial cells and smooth muscle cells. Marelli et al. [68] electrospun silk 
fibroin grafts (6 mm ID) and reported higher mean compliance of SF grafts than both Goretex and Dacron 
grafts and bovine heterografts along with good in-vitro cytocompatibility. Blends of SF with other 
polymeric fibres have been investigated for small diameter graft by Wang et al. [69] who produced a tubular 
scaffold composed of polylactide fibers (outside layer) and silk fibroin-gelatin fibers (inner layer) using 
electrospinning. 
Polyurethane presented another field of polymer based innovative vascular grafts for many as well. 
Uttayarat et al. [70] developed electrospinning techniques to pattern the luminal surface of small-diameter 
polyurethane (PU) grafts with microfibres and evaluated endothelial cell orientation later. Endothelial cells 
seeded onto the grafts formed confluent monolayers with elongated cell morphology parallel to the 
developed micro-patterns. Detta et al. [71] developed small diameter grafts by electrospinning an elastomeric 
polyurethane (Tecoflex EG-80A) and gelatin from different spinnerets on a rotating mandrel. The composite 
graft was reported to have enhanced endothelial cells adhesion and proliferation, compared to Tecoflex mesh 
alone. 
The challenges for using electrospun fibres include controlling appropriate cell populations and 
controlling the effects of matrix composition and signalling on the cells of interest. This is finally dependent 
on accurate control of fibre deposition on surface. Also, the best fibre diameter or interfibre distance to 
achieve an optimized cell function, remains a topic of further research. This has led researchers to investigate 
polymer-ceramic composite fibres and thermal treatments to enhance fibre bonding [72]. It may be required 
to develop 3D scaffolds that incorporate layered structures e.g., random and aligned fibre layers that could 
provide cell niches as well as regions for contact guidance. Currently, although numerous studies have 
demonstrated the great potential of electrospun fibrous materials, fewer in-vivo studies have been carried out. 
4. Summary and future outlook 
The quest for an ideal small calibre vascular graft has been continuing from over 50 years and is still 
persistent. Replication of the unique properties of arterial structures, i.e. optimum mechanical and biologic 
responses, remains a challenging task from engineering and biological aspects of vascular graft design. 
Synthetic grafts (Dacron knitted and woven) based on tubular three dimensional configuration are being 
commonly used in high pressure, high flow blood vessels like the aorta (Abdominal and Thoracic) and 
femoral arteries in thighs. However, they have not been as successful in other regions like carotid and heart 
bypass surgeries. This has led to development of a new generation of polymers like polyurethanes for 
biomedical use which are more compliant than Dacron and ePTFE grafts. However, no synthetic alternative 
has been found to compare with the patency rates of gold-standard autologous conduits. But unavailability of 
native grafts in most of the times shifts the focus towards biologically engineered vascular grafts as the only 
alternative. Biohybrid and tissue-engineered vascular grafts have been manufactured with the help of 
materials research, complex tissue culture and cell seeding technologies. The outcomes of experimental and 
clinical tissue engineered implants have been favourable and this technology can become a preferred option 
in vascular and endovascular surgery in the coming decades. Simultaneously, developments in three 
dimensional nanofibrous structures have begun to show a positive impact on tissue engineering by offering a 
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unique scaffold surface for cell growth. In order to fully realize the potential of electrospun fibres, three-
dimensional (3D) fibrous microstructures will play an important role in improving the performance of these 
implants. In conclusion, three dimensional textile structures have become an integral part of biomedical 
textiles. They offer an interdisciplinary field of research for biomedical scientists and textile engineers. 
Further, 3D electrospun structures will continue to provide artificial vascular grafts with improved surface 
morphologies that support cell growth, mimicking the functional and mechanical properties of native arteries. 
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